Skip to main content

Standardization of Immunohistochemical Staining Methods

This document explains the critical importance of standardizing immunohistochemistry (IHC) and in situ hybridization (ISH) techniques in pathology laboratories. It details how pre-analytical variables, such as fixation and tissue processing, significantly impact diagnostic accuracy. The text also covers predictive and

Save this reading to your study set

Sign up free

In the modern pathology laboratory, the ability to visualize specific proteins and nucleic acids within tissue sections is a cornerstone of precision medicine. Immunohistochemistry (IHC) and In Situ Hybridization (ISH) allow clinicians to look beyond general cell morphology to identify the molecular drivers of disease. However, the transition from a tissue biopsy to a diagnostic result is fraught with potential errors. Because these techniques are increasingly used to guide life-altering treatments, the standardization of all variables—particularly those occurring before the staining begins—is not merely a matter of laboratory efficiency; it is a fundamental requirement for patient safety.

The Clinical Stakes: Predictive and Prognostic Markers

The primary driver behind the push for rigorous standardization is the shift in how biomarkers are used in clinical practice. We no longer use IHC solely to identify the type of tumor a patient has; we use it to determine how that tumor will behave and which drugs will work.

Biomarkers are generally categorized into two functional roles:

  1. Prognostic Markers: These provide information about the likely course of the disease (e.g., how aggressive a tumor is) regardless of the treatment chosen.
  2. Predictive Markers: These are perhaps more critical for modern oncology. They identify whether a patient is likely to respond to a specific targeted therapy.

For example, in breast cancer diagnostics, several key proteins serve as essential predictive markers:

  • HER2 (human epidermal growth factor receptor 2): High expression of this protein indicates that a patient may benefit from HER2-targeted therapies, such as trastuzumab.
  • ER (Estrogen Receptor) and PgR (Progesterone Receptor): The presence of these receptors helps clinicians decide if hormone therapy will be an effective treatment strategy.

Keep reading for free.

Create an account to finish this reading and make it part of your study routine.

Continue reading free

Already have an account? Log in

Updated

Study it your way.

Import this reading into your study set to get started with another study mode.

Make it your own.

Keep this reading in a new study set, or add it to one you already use.